amrubicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antineoplastics, daunorubicin derivatives | 202 | 110267-81-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Amrubicin is a third-generation anthracycline and potent topoisomerase II inhibitor, for used in the treatment of small-cell lung cancer (SCLC) in Japan.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01DB10 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances |
| MeSH PA | D000970 | Antineoplastic Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
| CHEBI has role | CHEBI:50266 | Prodrugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.12 | acidic |
| pKa2 | 9.39 | acidic |
| pKa3 | 10.45 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D08854 | KEGG_DRUG |
| 110311-30-3 | SECONDARY_CAS_RN |
| C0762659 | UMLSCUI |
| CHEBI:135779 | CHEBI |
| CHEMBL1186894 | ChEMBL_ID |
| CHEMBL481958 | ChEMBL_ID |
| DB06263 | DRUGBANK_ID |
| C055866 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6802 | INN_ID |
| 93N13LB4Z2 | UNII |
| 3035016 | PUBCHEM_CID |
Pharmaceutical products:
None